In particular, compound 23 showed significant antiproliferative effects (IC50 in the range 1–5 μM) especially on cancer cell lines characterized by c-Met overexpression (ICMKN45, SNU-5 and H1993), exhibiting a promising PK profile and a remarkable in vivo tumour growth inhibition in human glioblastoma xenograft models [55]. Here, MET is linked to cancer.